TY - JOUR AU - Abidin, Farooq Ul AU - Sarfraz, Muhammad Haroon AU - Javaid, Hassaan AU - Khan, Asfandyar AU - Khan, Summaya AU - Javaid, Haroon PY - 2022/02/28 Y2 - 2024/03/29 TI - Therapeutic Efficacy of Topical Olopatadine 0.1% Versus Ketotifen Fumarate in Allergic Conjunctivitis JF - Pakistan Armed Forces Medical Journal JA - PAFMJ VL - 72 IS - 1 SE - Original Articles DO - 10.51253/pafmj.v72i1.6324 UR - https://pafmj.org/PAFMJ/article/view/6324 SP - 16-19 AB - <p><strong>Objective:</strong> To compare the therapeutic efficacy of topical Olopatadine 0.1% versus Ketotifen Fumarate among the patients diagnosed with allergic conjunctivitis at Armed forces institute of ophthalmology.</p><p><strong>Study Design:</strong> Prospective comparative study.</p><p><strong>Place and Duration of Study:</strong> Armed forces Institute of Ophthalmology, Rawalpindi, from Jan 2020 to Jan 2021.</p><p><strong>Methodology:</strong> Patients diagnosed with allergic conjunctivitis by consultant ophthalmologist fulfilling the exclusion/inclusion criteria were included in the study. They were divided into two groups by block randomization with group A receiving Olopatadine 0.1%, while group B just received the Ketotifen Fumarate. Symptoms were assessed on a symptom severity score upon diagnosis before the start of medication and then after 72 hours of treatment by a different consultant ophthalmologist who was unaware of the group of patients.</p><p><strong>Results:</strong> A total of 100 patients were included in each group. The mean age of the study participants was 30.944 ± 3.349 years. 148 (74%) patients were males while 52 (26%) were females. The difference in mean score of symptoms in group A was 5.76 ± 1.39 while in group B was 3.33 ± 2.51. Application of t-test revealed that topical Olopatadine 0.1% was superior to Ketotifen Fumarate in reducing the symptoms of acute allergic conjunctivitis on the third day of treatment (p-value&lt;0.001).</p><p><strong>Conclusion:</strong> Seasonal allergic conjunctivitis was the commonest type of allergic conjunctivitis seen in our study participants. Topical Olopatadine 0.1% emerged as a better treatment option when compared to Ketotifen Fumarate for immediate management of acute allergic conjunctivitis among patients managed at a tertiary...................</p> ER -